Invion Ltd
ASX:IVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 5-Year Average (66.7), the stock would be worth AU$0 (100% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | AU$0.06 |
0%
|
| 5-Year Average | 66.7 | AU$0 |
-100%
|
| Industry Average | 29.3 | AU$0 |
-100%
|
| Country Average | 5.8 | AU$0 |
-100%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Invion Ltd
ASX:IVX
|
6.1m AUD | 0 | -0.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 16.9 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 8.8 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 6.3 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 6.4 | 28.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 5.7 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 7.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 160.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.2 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 4.2 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 4.4 | 17.3 |
Market Distribution
Other Multiples
Invion Ltd
Glance View
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatments for market opportunities in a variety of cancer indications, chronic inflammatory, and autoimmune diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is focused on the development of Photosoft technology for the treatment of a range of cancers. The firm is conducting various clinical trials for the development of its Photosoft technology. Its Photo Dynamic Therapy (PDT) is a treatment that optimizes the use of non-toxic photosensitizers and visible light to kill cancer and stimulate the immune system. The firm aims to develop photosensitizer, IVX-PDT, that improves the treatment of skin cancers and hard-to-treat solid cancers, such as those present in ovarian, prostate and lungs. Epitech Dermal Science Pty Ltd is the wholly owned subsidiary of the Company.
